NCERT grounding
NCERT Class 12 Biology, Section 7.2.4 Vaccination and Immunisation (page 127), opens the topic with a single, exam-critical sentence: the principle of immunisation is based on the memory property of the immune system. The chapter then bundles four operational threads together — antigenic preparations as vaccines, the anamnestic response on re-exposure, preformed-antibody therapy for tetanus and snakebite, and the recombinant hepatitis-B vaccine produced in yeast. NIOS Lesson 31 (Immunobiology) supplements this with vaccine classification (killed, live-attenuated, toxoid) and the Edward Jenner cowpox-smallpox backstory that gives "vaccination" its name (Latin vacca = cow).
"The vaccines also generate memory B- and T-cells that recognise the pathogen quickly on subsequent exposure and overwhelm the invaders with a massive production of antibodies."
— NCERT Class 12, Chapter 7, Section 7.2.4
Principle, active and passive immunisation
The memory principle
A naive immune system mounts a primary response the first time it meets an antigen. This response is slow — antibody titre rises only after a lag of several days, peaks modestly, and is dominated by IgM. While the immune system is climbing this learning curve, a virulent pathogen can replicate freely and cause disease. Vaccination short-circuits the problem: it lets the body run its primary response against a harmless version of the antigen so that, when the real pathogen arrives, the response is no longer primary but secondary (anamnestic) — faster, larger, IgG-dominated, and almost always pre-emptive.
The cellular substrate of this memory is the long-lived memory B and memory T cells seeded during the primary response. NCERT phrases this exactly: vaccines "generate memory — B and T-cells that recognise the pathogen quickly on subsequent exposure and overwhelm the invaders with a massive production of antibodies." This is the same anamnestic response NEET 2022 tested in a four-statement question on acquired immunity.
A vaccine therefore needs to do two things and only two things: (i) carry the same antigenic shape (epitope) as the real pathogen, and (ii) be unable to cause disease. How a manufacturer achieves the second condition gives rise to the vaccine taxonomy below.
Figure 1. A vaccine triggers the small red curve (primary, lagged, mostly IgM). Memory cells laid down at this stage convert any subsequent natural infection into the steep green curve (secondary anamnestic, IgG-dominated), neutralising the pathogen before clinical disease can develop.
Active immunisation — slow, durable, memory-forming
In active immunisation the host actively makes its own antibodies because it has been deliberately exposed to an antigen. The antigen can be a killed organism (typhoid, cholera, pertussis, rabies, injectable polio), a live but weakened organism (BCG against tuberculosis, oral polio, measles, rubella, MMR), a toxoid (diphtheria, tetanus), or a recombinant antigenic protein (hepatitis B). Antibody titres take days to weeks to climb, but the protection generated is long-lived because memory B and T cells persist for years.
NCERT also includes naturally acquired active immunity within this bucket: a person who recovers from a wild infection (for example chickenpox or measles) similarly generates antibody and memory cells. Both deliberate vaccination and natural infection are "active" because the work of antibody production is done by the host.
How an active vaccine works — five-step cascade
-
Step 1
Antigen introduced
Killed/attenuated pathogen or recombinant protein injected. No disease produced.
-
Step 2
APC presentation
Macrophages and dendritic cells engulf and present epitopes on MHC-II to helper T cells.
-
Step 3
Clonal selection
Antigen-specific B and T cells proliferate; primary response unfolds over 7–14 days.
-
Step 4
Memory pool seeded
Long-lived memory B and memory T cells persist in lymphoid organs for years to decades.
-
Step 5
Anamnestic strike
Real pathogen meets pre-armed memory cells: high-titre IgG cleared the invader within hours.
Passive immunisation — fast, short-lived, no memory
In passive immunisation, antibodies are not synthesised by the recipient — they are borrowed. Pre-made (preformed) antibodies are obtained from an immunised animal or human donor, purified, and injected into the patient. Protection is essentially instantaneous because the antibody is already at therapeutic concentration the moment the syringe is empty. The cost of that speed is that no memory cells are generated and the antibody is cleared from circulation within a few weeks, so future exposures need a fresh dose.
NCERT names three classic indications where speed matters more than durability:
- Tetanus toxin exposure — anti-tetanus serum (an antitoxin, i.e. a preparation of antibodies against the toxin) is given immediately after a deep wound.
- Snakebite — anti-snake-venom (polyvalent antivenom) is the textbook example of preformed antibodies in NCERT and was tested verbatim in NEET 2016.
- Post-exposure rabies, diphtheria, hepatitis B — immunoglobulin is co-administered with the active vaccine to buy time while the active response builds.
Naturally acquired passive immunity also exists. Maternal IgG crosses the placenta and protects the foetus and newborn for several months, while IgA in colostrum coats the breastfed infant's gut and respiratory mucosa. NEET 2019 asked exactly this — colostrum confers passive immunity to the infant via IgA.
Active
Host makes Ab
Antigen exposure
- Antigen given (vaccine or infection)
- Onset slow (days–weeks)
- Long-lasting protection (years)
- Memory B and T cells generated
- Examples: BCG, OPV, hepatitis B, MMR, DPT
Passive
Pre-made Ab given
Antibody transfer
- Preformed antibody transferred
- Onset immediate (minutes)
- Short-lived protection (weeks)
- No memory generated
- Examples: anti-tetanus serum, antivenom, IgA in colostrum
Recombinant DNA vaccines
Conventional vaccines require culturing the pathogen itself — a costly, often hazardous step for organisms like hepatitis B virus that do not grow easily in cell culture. Recombinant DNA technology sidesteps this entirely: the gene encoding a single antigenic surface protein of the pathogen is cloned into a microbial host (typically yeast, Saccharomyces cerevisiae), which then secretes the antigenic polypeptide in bulk. The purified protein is the vaccine. NCERT explicitly cites the hepatitis B vaccine produced in yeast as the worked example. The same recombinant-platform logic underlies several modern vaccines and overlaps with the biotechnology-in-medicine syllabus.
Figure 2. The hepatitis-B surface antigen (HBsAg) gene is cloned into a plasmid, transformed into Saccharomyces cerevisiae, and the protein purified from the yeast culture. No live virus is ever handled — this is the NCERT textbook example of a recombinant-DNA vaccine.
Eradication, mass immunisation and the Indian programme
Sustained mass-immunisation programmes have rewritten global disease maps. Smallpox, the disease that gave Edward Jenner the original cowpox-vaccination idea in 1796, was declared eradicated by the World Health Organisation in 1980. The campaign succeeded because the smallpox virus had no animal reservoir, a single stable antigenic form, and an extremely effective live-attenuated vaccine. Polio, with a roughly similar epidemiological profile, has been pushed to the brink of eradication — India was certified polio-free in 2014, an achievement built almost entirely on oral polio drops (OPV, live attenuated). The Government of India's Universal Immunization Programme (UIP) delivers BCG (tuberculosis), DPT (diphtheria, pertussis, tetanus), OPV, measles, hepatitis B, rotavirus, and Hib free of cost to every child.
Smallpox eradication declared
The WHO confirmed global eradication of smallpox in 1980 following a decade-long ring-vaccination programme with the live vaccinia (cowpox-derived) vaccine — the only human disease eliminated worldwide by immunisation.
Vaccine taxonomy at a glance
Subject to the NIOS supplement which expands beyond NCERT's main-text examples, all currently used active vaccines fall into four categories. Memorise both the platform and at least one example, since matching-type NEET items routinely test the latter.
Killed (inactivated)
Pathogen killed by heat or chemicals — safe, multiple doses needed.
Examples: typhoid, cholera, pertussis, IPV (Salk), rabies.
Live attenuated
Pathogen weakened but still replicating — strong, durable, single dose often enough.
Examples: BCG, OPV (Sabin), measles, mumps, rubella, MMR.
Toxoid
Inactivated exotoxin — immunogenic but non-toxic.
Examples: tetanus toxoid, diphtheria toxoid (the T and D in DPT).
Recombinant DNA
Antigenic protein expressed in a microbial host — pure, scalable, no live pathogen.
Examples: hepatitis B (yeast), HPV.
Worked examples
Q. A child presents with a deep puncture wound from a rusty nail. The casualty officer administers (i) tetanus toxoid and (ii) tetanus antitoxin (immunoglobulin). Classify each as active or passive immunisation and justify.
A. The tetanus toxoid is an inactivated form of the Clostridium tetani exotoxin. It is an antigen and triggers the child's own immune system to produce antitoxin antibodies and memory cells — therefore it is active immunisation (slow onset, long-lasting). The tetanus antitoxin is a preparation of preformed antibodies against the toxin, transferred ready-made; this gives instant neutralisation of any toxin already in the wound and is passive immunisation (immediate onset, weeks of cover, no memory). Combining the two is standard practice precisely because the active response is too slow to neutralise the highly potent tetanospasmin.
Q. The hepatitis B vaccine is described in NCERT as a recombinant-DNA vaccine produced in yeast. Outline in three steps how this differs from a traditional killed-virus vaccine such as the Salk polio shot, and state one advantage of the recombinant route.
A. (i) In the Salk vaccine the whole poliovirus is grown in cell culture and then inactivated with formalin; the entire dead virion is injected. (ii) In the hepatitis-B vaccine only the gene for the surface antigen HBsAg is cloned into a plasmid, transformed into Saccharomyces cerevisiae, and the antigenic polypeptide is expressed by the yeast and purified — no virus is ever handled. (iii) The product is therefore a single, pure protein rather than a whole organism. Advantage: bulk production is cheap and safe because no infectious virus is cultured, allowing wide availability for mass immunisation (NCERT phrasing).
Q. A newborn breastfed for the first three days receives a yellowish fluid called colostrum. Identify the principal protective immunoglobulin in colostrum and explain what type of immunisation this represents.
A. Colostrum is rich in immunoglobulin A (IgA). IgA is secreted across the infant's gut and respiratory mucosa and neutralises pathogens at the surface. Because the antibody is transferred ready-made from mother to infant (the infant does not synthesise it), this is naturally acquired passive immunisation. Protection lasts only as long as breastfeeding continues plus a short half-life beyond — the infant must develop its own active immunity through routine vaccination and exposure over the first year of life. (Tested directly in NEET 2019, Q.2.)